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A COST-EFFECTIVENESS ANALYSIS OF
ELETRIPTAN 40MG AND 80MG VERSUS
SUMATRIPTAN 50MG AND 100MG IN THE
ACUTE TREATMENT OF MIGRAINE
Wells NEJ1, Drummond MF2
1Pﬁzer Global Research and Development, Sandwich, Kent,
United Kingdom; 2Innovus Research (UK) Ltd., and University
of York,York, United Kingdom
OBJECTIVES: To explore the application of cost-effec-
tiveness analysis in a comparison of eletriptan and suma-
triptan in the acute treatment of migraine employing a
composite measure of treatment outcome. METHODS:
The study is based on data from a randomised, double-
blind. placebo-controlled clinical trial comparison of oral
eletriptan (40mg and 80mg) and oral sumatriptan (50mg
and 100mg). The cost effectiveness analysis was under-
taken using the concept of “sustained pain-free” (SPF) 
to measure the outcome of treatment. SPF identiﬁes 
successful treatment as the combination of pain free
headache status at 2 hours after dosing, no recurrence
within 24 hours and no use of rescue medication. With
regard to costs, reﬂecting the health care system perspec-
tive of the analysis, drug costs for initial dosing, second
dosing for non-response and recurrence as well as the
costs of any rescue medication were taken into account.
RESULTS: The analysis found that eletriptan resulted in
lower costs per successfully treated attack (CPSTA) than
sumatriptan. The CPSTA values for the eletriptan 40mg
and 80mg groups were £17.55 and £31.76 compared
with ﬁgures for sumatriptan 50mg and 100mg of £63.98
and £80.50 respectively. All comparisons were statisti-
cally signiﬁcant (p < 0.024). CONCLUSIONS: The study
indicates that cost-effectiveness analysis can offer a
helpful framework for investigating the value-for-money
offered by the growing number of medicines for treating
migraine attacks. More speciﬁcally, its application to a
comparison of eletriptan and sumatriptan suggests that
the CPSTA for eletriptan 40mg is 27% of that found for
sumatriptan 50mg. Comparing eletriptan 80mg and
sumatriptan 100mg the corresponding value is 39%.
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ALZHEIMER’S DISEASE COST OF TREATMENT
STUDY (ADCOT) IN THE UNITED KINGDOM
Evans M1, Squires N2, Yuen C2
1Clatterbridge Hospital, Wirral, United Kingdom; 2Janssen-Cilag
Ltd, Buckinghamshire, United Kingdom
OBJECTIVES: To assess the resource utilisation of 
mild (MMSE 18 to 24), moderate (MMSE 11 to 17) and
severe (MMSE < 11), non-institutionalised patients with
Alzheimer’s disease in comparison with age, gender and
non-dementia disease-matched subjects. METHODS:
Resource utilisation data were collected on 146 patients
in the UK (120 with Alzheimer’s disease) by retrospective
review of clinical notes for a period of six months prior
to study entry, and by a single interview with the patient
and their carers. Direct medical resource use included
costs of hospitalisation, short-term institutionalisation,
medical consultations and medication. For direct non-
medical costs, utilisation of social services, equipment and
home modiﬁcations, personal expenses and transport
costs related to the illness were measured. For indirect
costs, time spent by the caregiver with the patient,
working days and productivity loss were evaluated. Costs
were assigned using 2001 UK pound sterling values.
RESULTS: Over the 6 month period, the total mean cost
per control subject was £1663 compared to £10,948 per
patient with mild, £14,176 per patient with moderate and
£16,626 per patient with severe Alzheimer’s disease. The
indirect cost of caregiving for Alzheimer’s patients was
the main component in all disease groups and represented
76%, 79%, and 70% of the total cost in the mild, 
moderate and severe disease groups, respectively. Within
direct costs, the contribution of short-term institutional-
isation accounted for 9% of total costs in the mild group,
increasing to 17% in the moderate and 34% in the severe
group (no control subjects required short-term institu-
tionalisation). Similarly, cost of hospitalisations increased
from 19% for patients with mild disease to 34% for
severe patients (4% for control group). CONCLUSIONS:
Resource utilisation by Alzheimer’s dementia patients is
signiﬁcantly greater than those without dementia and
increases with progression of disease.
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TIME SPENT AND COST ON INFORMAL CARE
GIVING FOR PERSONS WITH ALZHEIMER IN
SPAIN
Lopez Bastida J, Serrano Aguilar P,Yanes Lopez V,
Duque González B
Canarian Health Service, Santa Cruz de Tenerife, S/C de
Tenerife, Spain
OBJECTIVE: The objective of this study was to explore
the time spent and cost on caring by families of persons
with Alzheimer in Spain. METHODS: Questionnaires
were answered by 86 carers, caring for persons with
Alzheimer disease. Questions were focused on time spent
on caring: activities in daily living (ADL), instrumental
ADL (IADL), Social/recreational and Behaviour manage-
ment. The opportunity and replacement costs approaches
of informal care that occurred in 2001 in Spain were also
estimated. Disease stage was determined using the Clini-
cal Dementia Rating (CDR) scale. RESULTS: Informal
care, measured as hours spent caring, was about 293
hours per month for primary and secondary caregivers.
Approximately 32, 46, 9, and 16% of the total time of
informal support in ADL, IADL, Social/recreation and
Behaviour respectively. Informal care hours for mild,
moderate and severe Alzheimer patients were 196, 268
and 416 hours per month respectively. From the oppor-
tunity cost approach the annual cost for caregivers for
severe, moderate and mild patients were 16,274, 10,484
